Ani Pharmaceuticals Inc (ANIP)
| Market Cap | 1.65B-21.5% |
| Revenue (ttm) | 978.38M |
| Net Income | 99.60M |
| EPS | 4.62 |
| Shares Out | 22.96M |
| PE Ratio | 15.57 |
| Forward PE | 7.08 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 437,597 |
| Open | 71.72 |
| Previous Close | 71.52 |
| Day's Range | 71.57 - 72.74 |
| 52-Week Range | 69.58 - 97.00 |
| Beta | 0.49 |
| Analysts | Buy |
| Price Target | 105.78(+47.06%) |
| Earnings Date | Nov 6, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ANIP stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ANIP holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ANIP's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ANIP Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ANIP Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Cortrophin Gel | $117.13M | 44.03% |
| Generic pharmaceutical products | $99.05M | 37.23% |
| ILUVIEN and YUTIQ | $18.72M | 7.04% |
| Brand royalties and other revenues | $17.73M | 6.66% |
| Brands | $11.81M | 4.44% |
| Other generic revenues | $1.60M | 0.60% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ANIP patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ANIP from public contracts
Source: USAspending.gov
ANIP Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ANIP’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score